Equity · Healthcare
AVIR
NASDAQAtea Pharmaceuticals (AVIR)
The line runs 5.08 USD on 12 August through 4.41 USD on 9 November, on a scale from 4.0 to 6.0. Days the market did not trade hold the previous close, flat.
- Market cap
- 354.1M USD
- EPS, diluted, year to Dec 2025
- −1.94 USD
- 52-week range
- 3 USD – 6.12 USD
- Avg volume
- 27.1K
as of Nov 9, 2026
Have Atea Pharmaceuticals (AVIR) insiders bought or sold shares recently?
AVIR's newest Form 4 filing is dated 18 June 2026: none in the last 90 days.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 18 May 2026 | Murphy Polly A.Director | Buy | 6,100 | 25K USD |
20 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 18 Jun 2026 | Lucidi BrunoDirector | Option exercise | 29,600 | |
| 18 Jun 2026 | BERGER FRANKLIN MDirector | Option exercise | 29,600 | |
| 18 Jun 2026 | DUNCAN BARBARA GAYLEDirector | Option exercise | 29,600 | |
| 18 Jun 2026 | Adams Jerome M.Director | Option exercise | 29,600 | |
| 18 Jun 2026 | Polsky BruceDirector | Option exercise | 29,600 | |
| 18 Jun 2026 | Murphy Polly A.Director | Option exercise | 29,600 | |
| 11 Mar 2026 | Corcoran AndreaSee Remarks | Option exercise | 60,000 | 74K USD |
| 03 Feb 2026 | Sommadossi Jean-PierrePresident, CEO, and Chairman | Option exercise | 300,000 | 372K USD |
| 31 Jan 2026 | Horga Maria ArantxaChief Medical Officer | Option exercise | 51,283 | |
| 31 Jan 2026 | Horga Maria ArantxaChief Medical Officer | Tax withheld | 16,073 | 68K USD |
| 31 Jan 2026 | Vavricka JohnChief Commercial Officer | Option exercise | 42,083 | |
| 31 Jan 2026 | Vavricka JohnChief Commercial Officer | Tax withheld | 11,570 | 49K USD |
Showing the 12 most recent of 20 compensation filings in this window. The figures above count all of them.
Which funds hold Atea Pharmaceuticals (AVIR)?
6 of the 45 institutional funds we track reported a Atea Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined 17.2M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Two Sigma Investments | Held (±25%) | 1,506,697 | 7.0M USD | −19.2% |
| Renaissance Technologies | Held (±25%) | 1,131,200 | 5.3M USD | −3.0% |
| D. E. Shaw & Co. | Held (±25%) | 345,186 | 1.6M USD | −9.0% |
| Millennium Management | Held (±25%) | 304,611 | 1.4M USD | −13.0% |
| AQR Capital Management | Added | 247,710 | 1.2M USD | +437.2% |
| Citadel Advisors | Added | 157,224 | 731K USD | +224.8% |
| Point72 Asset Management | Exited |
What has been filed or recorded for Atea Pharmaceuticals (AVIR)?
The filings we hold for Atea Pharmaceuticals, newest first: 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.40 USD | |
| 30 Sep 2026 | Financials | Total assets | 200.7M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 175.7M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.41 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.57 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −1.94 USD | |
| 31 Dec 2025 | Financials | Net income | −158.3M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −1.94 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.53 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.44 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.40 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −2.00 USD |
What do people ask about Atea Pharmaceuticals (AVIR)?
What did Atea Pharmaceuticals shares close at?4.41
Atea Pharmaceuticals closed at 4.41 USD on 9 Nov 2026, up 2.32% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Atea Pharmaceuticals’ market cap?354.1M
Atea Pharmaceuticals is worth 354.1M USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.
Have Atea Pharmaceuticals insiders bought or sold shares recently?
No Atea Pharmaceuticals insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 18 Jun 2026 (SEC Form 4). See Insiders
Which funds own Atea Pharmaceuticals?6 of 45
6 of the 45 funds we track reported a Atea Pharmaceuticals position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Two Sigma Investments, Renaissance Technologies and D. E. Shaw & Co. See Funds
When did Atea Pharmaceuticals last report earnings?−0.40
Atea Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.40 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings